Abstract:Abstract Background The prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) has been greatly improved in the modern era of imatinib. Nevertheless, relapse is still a major cause of treatment failure in human Ph+ALL. Leukemia-initiating cells (LICs) are presumed to be responsible for relapse in leukemia. Therefore, we conducted a study to identify the candidate LICs that are responsible for disease progression and its clinical significance in patients with Ph+ALL. Aims To investigate the leukemia-initiating and self-renewal capacities of CD34+CD38-CD58- cells and determine the prognostic significance of CD34+CD38-CD58- phenotype in patients with Ph+ALL treated in Peking University Institute of Hematology. Methods The leukemia-initiating potential and self-renewal capacity of the sorted CD34+CD38-CD58-, CD34+CD38-CD58+,CD34+CD38+CD58- and CD34+CD38+CD58+ compartments were investigated in vivo using sublethally irradiated and anti-mouse CD122 monoclonal antibody conditioned NOD/SCID mice by intra-bone marrow–injection. Furthermore, we prospectively analyzed whether the identified CD34+CD38-CD58- compartment at diagnosis correlates with minimal residual disease (MRD) after therapy and clinical outcomes in 63 adult patients (18-60 years) with de novo Ph+ALL. Results Xenotransplantation of the sorted CD34+CD38-CD58- cells led to a repopulation of human B-ALL in primary and secondary recipient mice, which were phenotypically and clonally derived from the original Ph+ALL patients analyzed by flow cytometry, as well as quantitative real-time RT-PCR and fluorescence in situ hybridization for leukemia-specific cytogenetic abnormalities. Furthermore, the candidate CD34+CD38-CD58- LICs phenotype at diagnosis (n=16) significantly correlated with a lower complete remission rate and higher MRD frequency monitored by BCR-ABL mRNA levels in BM of Ph+ALL patients. Additionally, it directly correlated with higher cumulative incidence of relapse (CIR, 60% ± 1.97% vs. 15.51% ± 0.30%, P=0.002) and unfavorable disease-free survival (DFS, 33.75%±12.64% vs. 71.31%±7.17%, P=0.009) at 3-year. The CD34+CD38-CD58- group exhibited a higher rate of BCR-ABL mutations conferring higher level imatinib resistance than the other group (43.75% vs. 17.02%, P=0.04). Multivariate analyses revealed that CD34+CD38-CD58- phenotype at diagnosis was an independent risk factor for relapse (HR=4.35, P=0.009) and DFS (HR=3.38, P=0.008) in adult Ph+ALL. Summary/Conclusion Both the xenotransplantation data as well as the clinical correlation studies show that CD34+CD38-CD58- compartment enrich for leukemia-initiating cells in adult Ph+ALL. CD34+CD38-CD58- phenotype at diagnosis independently correlates with an adverse prognosis, which promises to be an efficient tool for relapse prediction and risk-stratification treatment in adult Ph+ALL patients. Acknowledgments This work was supported by grants from National Natural Science Foundation of China (grants no. 30800483&81230013) and Beijing Municipal Science and Technology Program (grant no.Z111107067311070). Disclosures: No relevant conflicts of interest to declare.

PLCB4 Upregulation is Associated with Unfavorable Prognosis in Pediatric Acute Myeloid Leukemia

Expression and Clinical Significance of Phospholipase D1 in De Novo Acute Myeloid Leukemia

Low Expression of ACLY Associates with Favorable Prognosis in Acute Myeloid Leukemia

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients with Acute Myeloid Leukemia.

Up-regulated Expression of Phospholipase C, β1 is Associated with Tumor Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma

LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia

The High-Risk Model Associated with SYTL4 Predicts Poor Prognosis and Correlates with Immune Infiltration in AML

Integrated analysis and validation reveal CYTH4 as a potential prognostic biomarker in acute myeloid leukemia

High Expression of BCL11A Predicts Poor Prognosis for Childhood MLL-r ALL

[Prognostic Factors of Pediatric Patients with Ph-positive Acute Lymphoblastic Leukemia].

PLCG1 is required for AML1-ETO leukemia stem cell self-renewal

[Analysis of Prognostic Variables in Childhood Acute Myeloid Leukemia].

Up-Regulation of A Hoxa-Pbx3 Homeobox-Gene Signature Following Down-Regulation of Mir-181 is Associated with Adverse Prognosis in Patients with Cytogenetically Abnormal Aml

SLC25A1-associated prognostic signature predicts poor survival in acute myeloid leukemia patients

High Expression of LOC541471, GDAP1, SOD1, and STK25 is Associated with Poor Overall Survival of Patients with Acute Myeloid Leukemia.

Upregulation of Microrna-125B Contributes to Leukemogenesis and Increases Drug Resistance in Pediatric Acute Promyelocytic Leukemia

Co-expression of ATP Binding Cassette Transporters is Associated with Poor Prognosis in Acute Myeloid Leukemia

miR-146a expression level as a novel putative prognostic marker for acute promyelocytic leukemia.

Gene coexpression network analysis revealed biomarkers correlated with blast cells and survival in acute myeloid leukemia

High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia

CD34+CD38-CD58- Candidate Leukemia-Initiating Cells Are Clinically Relevant with the Unfavorable Prognosis in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia